Century Therapeutics, Inc. financial data

Symbol
IPSC on Nasdaq
Location
Philadelphia, PA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 820% % 89%
Debt-to-equity 36% % -64%
Return On Equity -4.9% % 93%
Return On Assets -3.6% % 89%
Operating Margin -28% % 100%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 179,722,750 shares 109%
Common Stock, Shares, Outstanding 87,519,096 shares 2%
Entity Public Float $212,506,473 USD 0%
Common Stock, Value, Issued $9,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 86,556,515 shares 10%
Weighted Average Number of Shares Outstanding, Diluted 86,556,515 shares 10%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $114,898,000 USD 8287%
General and Administrative Expense $24,003,000 USD -28%
Operating Income (Loss) $17,269,000 USD 87%
Nonoperating Income (Expense) $7,621,000 USD -43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $9,648,000 USD 92%
Income Tax Expense (Benefit) $1,790,000 USD -4.8%
Net Income (Loss) Attributable to Parent $9,580,000 USD 92%
Earnings Per Share, Basic -0.14 USD/shares 91%
Earnings Per Share, Diluted -0.14 USD/shares 91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $61,853,000 USD 5.8%
Assets, Current $120,769,000 USD -38%
Property, Plant and Equipment, Net $50,026,000 USD -19%
Operating Lease, Right-of-Use Asset $16,139,000 USD -44%
Intangible Assets, Net (Excluding Goodwill) $34,200,000 USD 0%
Goodwill $4,727,000 USD
Assets $223,704,000 USD -37%
Accounts Payable, Current $4,773,000 USD 55%
Employee-related Liabilities, Current $4,632,000 USD -40%
Liabilities, Current $20,226,000 USD -84%
Deferred Income Tax Liabilities, Net $4,301,000 USD -1.7%
Operating Lease, Liability, Noncurrent $40,241,000 USD -18%
Liabilities $64,768,000 USD -66%
Accumulated Other Comprehensive Income (Loss), Net of Tax $30,000 USD -91%
Retained Earnings (Accumulated Deficit) $791,917,000 USD -1.2%
Stockholders' Equity Attributable to Parent $158,936,000 USD -1.5%
Liabilities and Equity $223,704,000 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,623,000 USD -14%
Net Cash Provided by (Used in) Financing Activities $120,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $27,930,000 USD 142%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 87,519,096 shares 2%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $65,011,000 USD 6.2%
Deferred Tax Assets, Valuation Allowance $197,809,000 USD 2.9%
Deferred Tax Assets, Gross $208,748,000 USD 0.01%
Operating Lease, Liability $43,565,000 USD -19%
Depreciation $13,101,000 USD -1.5%
Payments to Acquire Property, Plant, and Equipment $475,000 USD -12%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $9,874,000 USD 92%
Lessee, Operating Lease, Liability, to be Paid $63,946,000 USD -24%
Property, Plant and Equipment, Gross $98,626,000 USD 0.44%
Operating Lease, Liability, Current $3,324,000 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year Two $7,377,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year One $7,340,000 USD -25%
Operating Lease, Weighted Average Discount Rate, Percent 0.102 pure -1.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20,381,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,565,000 USD -21%
Deferred Tax Assets, Operating Loss Carryforwards $108,835,000 USD 78%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,756,000 USD -21%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $10,939,000 USD -34%
Share-based Payment Arrangement, Expense $6,840,000 USD -46%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%